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Abstract
Background: Tobacco smoking is a risk factor for several adverse post-operative outcomes. We aimed to compare
the rates of complications in current tobacco users and non-users who underwent primary total hip arthroplasty
(THA) or total knee arthroplasty (TKA).
Methods: All patients who underwent primary THA or TKA at the Mayo Clinic from 2010–2013 were included in
the study. Current tobacco use was defined as the use of cigarettes, cigars, pipes, or smokeless tobacco reported at
the time of index THA or TKA; current non-users were former users or never users. We used Cox proportional
hazards regression to assess the association of current tobacco use status with each post-THA/TKA complication,
using hazard ratios and 95 % confidence intervals (CI).
Results: Tobacco use status was available for 7926 patients (95 %) and not available for 446 patients (5 %); 565
(7 %) were current tobacco users. Compared to non-users, current tobacco users were more likely to be male (p < 0.001),
and less likely to be obese (p ≤ 0.008), be older than 60 years, have Charlson score >0 or have undergone TKA
rather than THA (p < 0.001 each). The hazard ratios for deep infection (2.37; 95 % CI 1.19, 4.72; p = 0.01) and
implant revision (1.78; 95 % CI 1.01, 3.13; p = 0.04) were higher in current tobacco users than in non-users. No
significant differences were noted for periprosthetic fractures or superficial infections.
Conclusions: We noted that current tobacco use was associated with high risk of deep infection and implant
revision after primary THA or TKA. Future studies should determine the optimal time for tobacco use cessation
before elective surgeries such as THA and TKA to improve short-term and long-term arthroplasty outcomes.
Keywords: Arthroplasty, Complications, Outcomes, Smoker, Smoking, THA, THR, TKA, TKR, Tobacco use, Total hip
replacement, Total knee replacement
Background
Tobacco smoking is a risk factor for several adverse
post-operative outcomes, including wound-related com-
plications, in part owing to its effect on tissue oxygen-
ation and inflammatory healing processes [1, 2]. For
example, in a study of >33,000 patients undergoing total
knee arthroplasty (THA) or total hip arthroplasty (TKA)
using the Veterans Affairs Surgical Quality Improvement
Program database, current smokers had higher risk of
30-day surgical site infections (SSIs) than non-smokers
[3]. However, studies describing the association of smok-
ing on short-term or long-term arthroplasty surgical
outcomes are limited.
In a study that included 621 patients, the rate of
arthroplasty revision was significantly higher in smokers
compared to non-smokers in univariate analyses [4];
rates of other surgical complications were no different
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between the groups [4]. However, the analyses were not
adjusted for other possibly important covariates such as
age, gender, or comorbidity. In contrast, another study
that examined the risk of implant revision in 1301 THA
patients found no association between smoking and revi-
sion risk in ceramic-on-polyethylene bearing primary
THA [5]. A systematic review of the effect of smoking
on outcomes after total joint replacement showed that
current smoking increased the risk of overall post-
operative complications and death but that there were
scarce data for smoking and surgical outcomes of
arthroplasty [6]. To our knowledge, well-designed stud-
ies that have examined the risk of post-arthroplasty
implant-related complications due to tobacco use are
lacking. A recent meta-analysis of studies assessing the
effect of smoking on THA outcomes acknowledged the
lack of a consistent definition of “current smoker,” ad-
justment for important covariates, and heterogeneity
among studies as key limitations [7].
The objective of this study was to assess the associ-
ation between tobacco use status and outcomes of TKA
or THA using data from an institutional Total Joint
Registry. We hypothesized that current tobacco use
would be associated with an increased risk of revision
surgery, wound infections, and peri-prosthetic fractures
after primary THA or TKA.
Methods
We followed the Strengthening of Reporting in
Observational studies in Epidemiology (STROBE)
statement to describe this study and results [8]. The
Institutional Review Board at Mayo Clinic, Rochester,
MN, approved the study and waived the requirement
for informed consent.
Setting, participants, and data sources
This observational cohort study included all patients who
underwent primary THA or TKA at Mayo Clinic from
2010 to 2013 and had tobacco use status documented in
the nursing database. We obtained data from two sources,
the Mayo Clinic Joint Registry and the nursing notes of
the Mayo Clinic electronic medical record.
The Mayo Clinic Joint Registry is a prospective registry
of all patients who undergo joint replacement surgery at
the Mayo Clinic, Rochester, MN [9, 10]. Each patient
who undergoes joint replacement surgery is followed
prospectively with clinical follow-up at one, two, and five
years, and every five years thereafter. Patients failing to
return for a follow-up visit are sent a questionnaire
(joint-specific) and asked to send in their radiographs.
Those who fail to return the questionnaire are contacted
on the telephone by trained registry staff. Patients undergo
a brief telephone interview using a standardized question-
naire including complications, such as infection, fracture,
and any additional surgery. Data, including the indication
for surgery and operative findings, are requested for sub-
sequent operations performed at other hospitals.
Using unique patient identifiers, we linked the tobacco
use status data from the Mayo Clinic Anesthesia data-
base to the Joint Registry. As a matter of routine clinical
assessment, tobacco use is consistently documented at
the time of admission for patients at all Mayo Clinic
hospitals in Rochester, MN, by admission nursing staff.
This includes whether patients are currently using to-
bacco, and the type of use (cigarette, cigar, pipe, or
smokeless tobacco use).
Predictor of interest
Current tobacco use status was the primary predictor of
interest. Current tobacco users were defined as people
who were using cigarettes, cigars, pipes, or smokeless to-
bacco at the time of their surgery, with the rest classified
as non-users. Thus, current non-users included both
never-users and former users.
Covariates
We included several covariates known/suspected to be
associated with complications after THA or TKA,
namely demographics (age, gender); body mass index
(BMI); American Society of Anesthesiologist (ASA)
class; implant fixation (uncemented, cemented, anti-
biotic/vacuum); and medical comorbidity assessed using
a validated Deyo–Charlson index [11], which is a
weighted scale of 17 comorbidities (including cardiac,
pulmonary, renal, hepatic disease, diabetes, cancer, HIV
and so on), expressed as a summative score where a
higher score indicates more comorbidity.
Outcomes of interest
The a priori outcomes were deep infection, superficial
infection, peri-prosthetic fracture, and the need for revi-
sion surgery. Exploratory outcomes included the reasons
for revision (aseptic loosening, infection, and peri-
prosthetic fracture). Deep infection was defined as infec-
tion below the fascia; other infections were categorized
as superficial infections. Peri-prosthetic fracture was de-
fined as the presence of proximal, distal, or both, or
avulsion fracture. Revision surgery was defined as the
occurrence of revision of one or more components of
the THA or TKA.
Sample size and potential bias
No formal sample size calculations were done, given the
lack of previous studies providing effect size estimates.
The Mayo Clinic Joint Registry includes every patient
who has undergone THA or TKA at the institution. We
anticipated that despite a large sample size, the rarity of
these complications would limit the ability to perform
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multivariable-adjusted analyses. We decided a priori that
where possible, we would adjust for the most important
significant covariates and confounders, and where not
possible, acknowledge this as a limitation. We selected a
large enough sample by choosing all eligible patients
from 2010 to 2013 to avoid a type II error. In very few
cases of simultaneous (or sequential) bilateral THA or
TKA in a patient, we used only one side (or the first
procedure) to avoid correlated observations.
Statistical analyses
Descriptive statistics were reported as number (percent-
age) or mean (standard deviation) as appropriate. Char-
acteristics of patients with and without known tobacco
use status were compared using logistic regression ana-
lyses, also done for current tobacco users versus non-
users. Odds ratios and 95 % confidence intervals (CI) are
presented. Cox proportional hazards regression was used
to assess the association of tobacco use status with each
outcome, reporting a hazard ratio (HR) and 95 % CI.
Kaplan–Meier (KM) survival was used to estimate im-
plant survival. The KM curves go to 25 months, because
the number at risk drops below 10 patients at 25 months.
A p-value of less than 0.05 was considered significant.
Results
Characteristics of patients with and without tobacco use
status data
Tobacco use status was available for 7926 patients
(95 %) and not available for 446 patients (5 %) undergo-
ing primary THA or TKA. Compared to those without
available tobacco use status assessment, patients with to-
bacco use data were more likely to be in the age groups
71–80 and >80 years (reference, age ≤60), and to be fe-
male; no significant differences were noted in BMI, im-
plant fixation, Deyo–Charlson index score, or ASA class
(Table 1).
Cohort characteristics
Of the 7926 patients, 565 (7 %) reported current tobacco
use, with 7361 (93 %) not currently using tobacco (in-
cluding never-users and past tobacco users). In the
group of 565 current tobacco users, only two patients
were classified as using smokeless tobacco only. In un-
adjusted analyses, compared to current tobacco non-
users, current tobacco users were more likely to be male
(p < 0.001), and less likely to be obese (p ≤ 0.008), older
than 60 years, have Charlson score >0 or have under-
gone TKA rather than THA (p < 0.001 each). (Table 2).
There were no significant differences in implant type
or ASA class (Table 2). The mean follow-up was
similar between current tobacco user and current to-
bacco non-users (349 versus 308 days, respectively).
Current tobacco use and the risk of post-THA/TKA
complications
In analyses that adjusted for joint type (THA versus
TKA), age, and sex, current tobacco users had signifi-
cantly higher hazard of deep infection, (HR 2.37; 95 %
CI 1.19, 4.72; p = 0.01) and implant revision (HR 1.78;
95 % CI 1.01, 3.13; p = 0.04) than current tobacco non-
users (Table 3). No significant differences in peripros-
thetic fractures and superficial infection were noted
(Table 3). The times free of implant revision and free of
deep infection by current tobacco use are shown in
Fig. 1a and b, respectively. In exploratory analyses, in a
fully adjusted model for joint type (THA versus TKA),
age, and sex, current users tended to be at higher risk of
revision for infection (HR 2.28; 95 % CI 0.99, 5.27; p =
0.05). Other exploratory outcomes occurred at much
lower frequencies that did not allow meaningful analyses
to be conducted, that is, revision owing to aseptic loos-
ening occurred only in 14 patients and revision owing to
peri-prosthetic fracture in only nine patients.
Discussion
Smoking can interfere with wound healing and increase
infection risk by multiple potential mechanisms, including
vasoconstriction, which can interfere with wound healing
[12]; fibroblast survival and migration at the site of healing
[13]; and carbon monoxide from smoking can lead to de-
creased oxygen delivery to tissues [14, 15], and oxygen is
needed for optimal wound healing [16]. In this study of
7926 primary THA or TKA patients, we found that
current tobacco use was associated with a significantly
higher risk of implant revision and deep infection. These
differences remained significant in multivariable-adjusted
models that included joint type, age, and gender.
Several prior studies have examined the effect of
smoking status on infectious complications in patients
undergoing total joint arthroplasty. In a study of 3908
patients with orthopedic implants, including THA and
TKA or fracture internal fixation devices, smoking was a
risk factor for SSIs for up to one year after surgery [17].
In our previous large study of 33,336 veterans who
underwent THA or TKA, current smokers had an ad-
justed odds ratio of 1.41 for 30-day SSIs compared to
never smokers [3]. In the current study, we found that
current tobacco users were at 2.37-times higher odds of
developing post-surgical deep infection compared to
current non-users. Our previous study [3] was per-
formed in veterans, who are sicker than the general
US population [18], but the current study cohort is
more representative of THA/TKA cohorts. Studies
that examined a related, but somewhat differently de-
fined outcome, that is, wound or local complications,
reported contradictory results—one study found
smoking was associated with wound complications
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with odds of 2.15 [19], while another found no differ-
ence in local complications between smokers and
non-smokers (3.8 % versus 3.8 %) [20]. A systematic
review of smoking and outcomes after total joint re-
placement showed that current smoking increased the
risk of any post-operative complication and death [6].
Another systematic review that included any surgery
showed that current smoking was associated with SSI
and wound complications with odds ratios of 1.79
(95 % 1.57–2.04) and 2.27 (95 % 1.82–2.84) [2].
Our finding that current smokers were younger and
had lower medical comorbidity than current non-
smokers is similar to the younger age and lower ASA
class in current smokers undergoing THA or TKA com-
pared to their counterparts in the Veterans Affairs study
of >33,000 patients [3].
Our study extends these studies of infectious compli-
cations by studying all-comers who underwent primary
THA or TKA at the Mayo Clinic, using a large sample,
examining superficial and deep infections separately, and
performing multivariable-adjusted analyses. Even though
we had a large sample size, the frequency of some com-
plications was low, which may have led to a type II error,
that is, lack of power, potentially explaining some nega-
tive findings. An interesting observation was that, even
when non-significant, odds ratios for several post-
operative complications ranged from 1.5 to 2.0 in
current tobacco users.
The most novel finding in our study was that current
tobacco users had 1.8-fold higher hazard of the risk of
revision arthroplasty than non-users, with 117 cases of
implant revision in a cohort of 7926 patients. Our find-
ing in univariate association was confirmed in
multivariable-adjusted analyses, suggesting that the find-
ing was robust. Our finding is in contrast to few previ-
ous studies [5, 21, 22] and agrees with one recent study
[4] showing the association of smoking and revision risk.
Espehaug et al. studied 1628 THA patients in a matched
case–control study from the Norwegian Arthroplasty
Register and found that current smokers had similar
Table 1 Comparison of characteristics of patients with and without current tobacco use assessment among patients who
underwent primary THA or TKA
Tobacco use assessed Tobacco use not assessed Odds Ratio p-value
(n = 7926) (n = 446) (95 % confidence interval)
N (%) N (%)
Knee 4,277 (94.5 %) 249 (5.5 %) 0.93 (0.76, 1.12) 0.44
Hip 3,649 (94.9 %) 197 (5.1 %) 1.0 (ref)
Male 3516 (94.1) 219 (5.9) 0.82 (0.68, 0.99) 0.04
Female 4410 (95.1) 227 (4.9) 1.0 (ref) a
Age ≤60 2430 (93.8) 161 (6.2) 1.0 (ref) a
61–70 2522 (94.2) 154 (5.8) 1.10 (0.88, 1.39) 0.40
71–80 2226 (95.5) 104 (4.5) 1.44 (1.12, 1.86) 0.005
>80 748 (96.5) 27 (3.5) 1.86 (1.22, 2.81) 0.004
BMI < 25 1177 (95.4) 57 (4.6) 1.0 (ref) a
25–29 2418 (94.4) 144 (5.6) 0.82 (0.60, 1.12) 0.21
30–34 2169 (95.2) 109 (4.8) 0.97 (0.70, 1.35) 0.86
35–39 1235 (94.4) 73 (5.6) 0.83 (0.58, 1.18) 0.30
≥40 889 (93.8) 59 (6.2) 0.74 (0.50, 1.08) 0.12
Cemented 2309 (94.6) 133 (5.4) 1.12 (0.71, 1.76) 0.62
Antibiotic/vacuum 2502 (94.6) 142 (5.4) 1.12 (0.74, 1.71) 0.59
No cement 3115 (94.8) 171 (5.2) 1.0 (ref) a
Charlson Index = 0 3734 (94.6) 212 (5.4) 1.0 (ref) a
>0 4192 (94.7) 234 (5.3) 1.02 (0.84, 1.24) 0.81
ASA = 1 231 (95.4) 11 (4.6) 1.0 (ref) a
2 5455 (94.8) 298 (5.2) 0.89 (0.48, 1.64) 0.70
3 2195 (94.3) 133 (5.7) 0.80 (0.43, 1.51) 0.49
4 42 (91.3) 4 (8.7) 0.51 (0.15, 1.66) 0.26
ASA American Society of Anesthesiologist, BMI body mass index in kg/m2, Ref reference category, SD standard deviation
a the model was adjusted for the joint type (TKA vs. THA)
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odds of 0.8 (95 % CI 0.5, 1.3) for reoperation as the non-
smokers [21]; study limitations were that smoking status
was assessed at the time of survey post-arthroplasty and
the definition of “early revision” was unclear. No associ-
ation between smoking and revision risk was found in
1301 patients (34 revisions) with ceramic-on-
polyethylene bearing primary THA, with odds ratio of
1.3 (95 % CI 0.6, 2.5) [5]. Meldrum et al. retrospectively
studied 147 patients with THA performed by a single
surgeon and found that in multivariable models adjusted
Table 2 Cohort characteristics of THA/TKA patients with and without current tobacco use
Current tobacco user Past tobacco user or
never used tobacco
Odds ratio p-value
(n = 565) (n = 7361) (95 % confidence interval)
N (%) N (%)
Knee 228 (5.0 %) 4049 (95.0 %) 0.55 (0.46, 0.66) <0.001
Hip 337 (8.8 %) 3312 (91.2 %) 1.0 (ref)
Male 326 (9.3) 3190 (90.7) 1.71 (1.44, 2.04) <0.001
Female 239 (5.4) 4171 (94.6) 1.0 (ref) a
Age ≤60 354 (14.6) 2076 (85.4) 1.0 (ref) a
61–70 143 (5.7) 2379 (94.3) 0.38 (0.30, 0.46) <0.001
71–80 56 (2.5) 2170 (97.5) 0.16 (0.12, 0.22) <0.001
>80 12 (1.6) 736 (98.4) 0.10 (0.06, 0.18) <0.001
BMI <25 118 (10.0) 1059 (90.0) 1.0 (ref) a
25–29 157 (6.5) 2261 (93.5) 0.66 (0.51, 0.85) 0.001
30–34 144 (6.6) 2025 (93.4) 0.70 (0.54, 0.91) 0.008
35–39 90 (7.3) 1145 (92.7) 0.82 (0.61, 1.09) 0.17
≥40 51 (5.7) 838 (94.3) 0.65 (0.46, 0.92) 0.02
Implant fixation
Cemented 124 (5.4) 2185 (94.6) 0.90 (0.62, 1.29) 0.57
Antibiotic/vacuum 151 (6.0) 2351 (94.0) 0.96 (0.69, 1.32) 0.81
No cement 290 (9.3) 2825 (90.7) 1.0 (ref) a
Charlson Index = 0 309 (8.3) 3425 (91.7) 1.0 (ref) a
>0 256 (6.1) 3936 (93.9) 0.76 (0.63, 0.90) 0.001
ASA class 1 18 (7.8) 213 (92.2) 1.0 (ref) a
2 393 (7.2) 5062 (92.8) 1.05 (0.64, 1.72) 0.85
3 148 (6.7) 2047 (93.3) 1.00 (0.60, 1.68) 0.99
4 5 (11.9) 37 (88.1) 1.72 (0.60, 4.95) 0.31
ASA American Society of Anesthesiologist, BMI body mass index in kg/m2, Ref Reference category, SD standard deviation
a the model was adjusted for the joint type (TKA vs. THA)









HR (95 % CI)a p-value HR (95 % CI)b p-value
Any revision Yes 16 95.8 (93.4, 98.3) 93.6 (90.5, 96.8) 1.98 (1.14, 3.46) 0.02 1.78 (1.01, 3.13) 0.04
No 111 98.2 (97.8, 98.6) 97.3 (96.7, 97.8) 1.0 (ref) 1.0 (ref)
Deep infection Yes 10 98.1 (96.8, 99.4) 97.0 (94.9, 99.0) 2.45 (1.25, 4.79) 0.009 2.37 (1.19, 4.72) 0.01
No 57 98.9 (98.6, 99.2) 98.7 (98.3, 99.0) 1.0 (ref) 1.0 (ref)
Superficial infection Yes 4 99.0 (98.1, 100) 99.0 (98.1, 100) 1.06 (0.38, 2.98) 0.92 1.07 (0.37, 3.09) 0.90
No 50 99.1 (98.8, 99.3) 99.1 (98.8, 99.3) 1.0 (ref) 1.0 (ref)
Peri-prosthetic fracture Yes 10 98.2 (97.0, 99.4) 98.2 (97.0, 99.4) 0.84 (0.44, 1.58) 0.59 1.01 (0.53, 1.92) 0.97
No 134 98.0 (97.6, 98.3) 97.7 (97.3, 98.2) 1.0 (ref) 1.0 (ref)
aCox models adjusted for knee (versus hip); bCox models adjusted for knee (versus hip), male (versus female), and age at surgery (per 1 year). Significant hazard
ratios and p-values are in bold
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for age, gender, BMI, diagnosis, stem fixation, and alco-
hol use, smokers had 4.5-times the hazard of revision
than non-smokers, a non-significant finding (p = 0.07)
[22]. A single-center study of 621 TKA patients with 18
revisions at mean follow-up of 4 years (131 current
smokers with 11 revisions) showed that the risk of revi-
sion in smokers was significantly higher than in non-
smokers [4]. Most previous studies of revision risk had
small sample sizes leading to potential type II error, that
is, missing a significant association when one is present,
owing to an underpowered study. Even with <60 revi-
sions due to infection, the HR related to current smok-
ing almost reached significance, 2.28 (95 % CI 0.99, 5.27;
p = 0.05). This correlates well with the biology and the
proposed pathophysiology of impaired healing due to
tobacco-related toxic effects on fibroblasts and other
cells needed for optimal wound healing [12–16].
Our study included a large sample from a Joint
Registry, with systematic data collection and monitor-
ing for complications. The higher overall revision risk
with current tobacco use may be mediated via a
higher rate of associated deep infections in the early
post-operative period; the borderline significance of
rates of revision for infection further supports this
hypothesis.
Our study had several limitations. Findings may not be
generalizable to other settings, because this was a single-
center study. However, the similarity of our THA/TKA
cohorts to other published studies of THA/TKA [23, 24]
as well as the US Nationwide Inpatient Sample [25],
Fig. 1 a Survival free of implant revision for any reason and b survival free of deep infection in current tobacco users (dashed line) compared
with current tobacco non-users (solid line). CI confidence interval, HR hazard ratio
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supports generalizability. Owing to the cohort study de-
sign, our study is subject to residual confounding. Con-
founding due to unmeasured factors among patients
undergoing THA/TKA compared to those who are de-
nied the surgery owing to higher medical comorbidity
needs to be considered while interpreting study findings.
Despite a large sample size, most outcomes of interest
were uncommon. Therefore, we likely missed some im-
portant associations owing to type II errors, that is,
missing an important observation when one existed be-
cause of small sample size. Larger sample sizes are
needed to definitively answer these questions. Pack-year
smoking history was not available for the majority of
patients and therefore could not be analyzed.
The number of patients only using smokeless tobacco
was extremely small (2 of the 565 current smokers),
therefore, no subgroup analyses could be performed by
the type of tobacco use. As with all observational stud-
ies, these findings need to be reproduced in other joint
registries of large size (state or country-based registries,
Kaiser Permanente etc.) that prospectively assess smok-
ing status and post-arthroplasty complications. Selection
bias needs to be considered while interpreting these
findings, because patients undergo pre-operative assess-
ment before having THA/TKA and it is possible that
those patients who underwent THA/TKA are healthier
than the age-matched and sex-matched general popula-
tion not undergoing these procedures, or patients who
undergo less invasive procedures. These findings should
not be generalized to the general population or those
populations undergoing less invasive procedures.
Conclusion
We confirmed that current smokers are at increased
risk for infectious complications after total joint
arthroplasty. In addition, we now show that current
smokers are also at risk for adverse functional out-
comes that require revision arthroplasty. It is well
established that tobacco use interventions reduce
perioperative risks in a variety of surgeries (including
orthopedic surgery) [26, 27]. Further studies would be
needed to determine if tobacco use intervention spe-
cifically can reduce the risk of deep infections and re-
vision surgery. However, because revision is a
relatively infrequent event, such studies would need
to be large. It would be more practical to have SSI or
wound complications as the primary outcome and re-
vision as the secondary outcome. Given the multiple
benefits of smoking cessation to both short-term and
long-term health, and that most primary TKA and
THA are elective, our findings provide further im-
petus for the routine application of effective tobacco
use interventions to all current smokers scheduled for
these procedures.
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